Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity.

Abstract:

:Valproic acid is approved for treatment of seizures and manic episodes of bipolar disorder, and continues to be one of the most commonly prescribed antiepileptic drugs in the world. Hepatotoxicity is a rare but serious side effect resulting from its use, particularly in young patients. This adverse effect does not display normal dose-response curves and can be lethal in children. A review of the purported mechanisms of action suggest hepatotoxicity results from increased oxidative stress, caused by a reduction in beta-oxidation and an increase in activation of certain metabolizing enzymes. There is also evidence that both carnitine and pantothenic acid are involved in the regulation of valproic acid-induced hepatotoxic processes, and clinical evidence has shown that treatment with either compound shows protective effects against hepatotoxicity. These results suggest a potential increase in protective effects with cotreatment of carnitine and pantothenic acid.

authors

Felker D,Lynn A,Wang S,Johnson DE

doi

10.1586/17512433.2014.871202

subject

Has Abstract

pub_date

2014-03-01 00:00:00

pages

211-8

issue

2

eissn

1751-2433

issn

1751-2441

journal_volume

7

pub_type

杂志文章,评审
  • Combating inappropriate use of medicines.

    abstract::Globally, it is possible that less than half of all patients are treated in compliance with guidelines and more than half of all patients fail to take their medicines as prescribed or dispensed. Such inappropriate use is wasteful of resources and causes patient harm in terms of lack of satisfactory outcome, serious ad...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.11.14

    authors: Holloway KA

    更新日期:2011-05-01 00:00:00

  • Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks.

    abstract:INTRODUCTION:Therapeutic efficiency of NSAID is handicapped by ongoing discussion of cardiovascular (CV) safety. Areas covered: We update meta-analyses on NSAIDs in patients with and without cardiovascular (CV) diseases and analyse the association between NSAIDs and cardiovascular events in patients with inflammation. ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2016.1230495

    authors: Zingler G,Hermann B,Fischer T,Herdegen T

    更新日期:2016-11-01 00:00:00

  • Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.

    abstract:INTRODUCTION:Induction chemotherapy based on anthracyclines and cytarabine (Ara-C) combination remains the standard of care for acute myeloid leukemia (AML) patients who are considered candidate for intensive and curative approaches. However, the toxicity of this regimen is high, with disappointing clinical outcomes am...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1080/17512433.2019.1573668

    authors: Megías-Vericat JE,Martínez-Cuadrón D,Sanz MÁ,Poveda JL,Montesinos P

    更新日期:2019-03-01 00:00:00

  • Immunotherapy for gastric cancers: emerging role and future perspectives.

    abstract:INTRODUCTION:The broad use of immunotherapy is revolutionizing the treatment paradigms of many solid tumors. Although chemotherapy remains the treatment backbone for advanced gastric cancer, improvements in its molecular characterization and progresses in understanding its underpinning biology have supported clinical d...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1313113

    authors: Bonotto M,Garattini SK,Basile D,Ongaro E,Fanotto V,Cattaneo M,Cortiula F,Iacono D,Cardellino GG,Pella N,Fasola G,Antonuzzo L,Silvestris N,Aprile G

    更新日期:2017-06-01 00:00:00

  • Tedizolid (torezolid) for the treatment of complicated skin and skin structure infections.

    abstract:INTRODUCTION:Acute bacterial skin and skin structure infections (ABSSSI) are among the most frequent infectious diseases. Recently, several new antibiotics with activity against MRSA have been approved. Tedizolid, a second-generation oxazolidinone approved for ABSSSI offers theoretical advantages over first-generation ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1774362

    authors: Carena AA,Stryjewski ME

    更新日期:2020-06-01 00:00:00

  • Methods for optimizing statistical analyses in pharmacogenomics research.

    abstract::Pharmacogenomics is a rapidly developing sector of human genetics research with arguably the highest potential for immediate benefit. There is a considerable body of evidence demonstrating that variability in drug-treatment response can be explained in part by genetic variation. Subsequently, much research has ensued ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.09.32

    authors: Turner SD,Crawford DC,Ritchie MD

    更新日期:2009-09-01 00:00:00

  • Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.

    abstract::Neuroblastoma (NB) is the most common extra cranial solid tumor of childhood, with 60% of patients presenting with high risk (HR) NB by means of clinical, pathological and biological features. The 5-year survival rate for HR-NB remains below 40%, with the majority of patients suffering relapse from chemorefractory tum...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1160775

    authors: Mora J

    更新日期:2016-01-01 00:00:00

  • Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits.

    abstract::Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are effective and widely used antihypertensive drugs. Exposure to these agents is known to be harmful to the fetus in the second and third trimesters of pregnancy. Concerns have also been raised about the risk of congenital malfo...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2015.1005074

    authors: Pucci M,Sarween N,Knox E,Lipkin G,Martin U

    更新日期:2015-03-01 00:00:00

  • Use of quantitative pharmacology tools to improve malaria treatments.

    abstract::The use of pharmacokinetic (PK) and pharmacodynamic (PD) data to inform antimalarial treatment regimens has accelerated in the past few decades, due in no small part to the stimulus provided by progressive development of parasite resistance to most of the currently available drugs. An understanding of the disposition,...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1129273

    authors: Davis TM,Moore BR,Salman S,Page-Sharp M,Batty KT,Manning L

    更新日期:2016-01-01 00:00:00

  • Pharmacological management of diabetic dyslipidemia.

    abstract:INTRODUCTION:Diabetes mellitus is associated with increased cardiovascular disease (CVD) risk. Areas covered: Main goal of hypolipidemic treatment in diabetic patients is low-density lipoprotein cholesterol (LDL-C) lowering with the use of statins. Addition of ezetimibe is useful in diabetic patients who cannot achieve...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1263565

    authors: Filippatos TD,Florentin M,Georgoula M,Elisaf MS

    更新日期:2017-02-01 00:00:00

  • JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.

    abstract::Introduction: Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease characterized by synovitis as well as symmetric and destructive arthropathy. Although several disease modified antirheumatic-drugs (DMARDs) have widely used in clinical practice, certain patients are nonresponsive to or cannot take suc...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1615443

    authors: Qiu Q,Feng Q,Tan X,Guo M

    更新日期:2019-06-01 00:00:00

  • Current perspectives on the modulation of thermo-TRP channels: new advances and therapeutic implications.

    abstract::The thermo transient receptor potential (TRP) ion channels, a recently discovered family of ion channels activated by temperature, are expressed in primary sensory nerve terminals, where they provide information regarding thermal changes in the environment. Six thermo-TRPs have been characterized to date: TRPV1-4, whi...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.10.41

    authors: Vay L,Gu C,McNaughton PA

    更新日期:2010-09-01 00:00:00

  • Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis.

    abstract::Introduction: Primary endpoints and inclusion/exclusion criteria of biologics and small oral molecules for psoriasis treatment have been evolving due to a better understanding of the pathogenesis and potential risks.Areas covered: We analyzed the designs of key phase 3 pivotal trials of all biologics and small oral mo...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1743175

    authors: Hsu SH,Tsai TF

    更新日期:2020-03-01 00:00:00

  • Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection.

    abstract:INTRODUCTION:Patients with moderate to severe COVID-19 infection require specific drugs to prevent the morbidity and mortality. Hydroxychloroquine (HCQ) has shown some promise in the management of COVID 19. Minocycline, because of its anticytokine and other useful properties can be an ideal candidate for combining with...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1832889

    authors: Gautam SS,Gautam CS,Garg VK,Singh H

    更新日期:2020-11-01 00:00:00

  • Clinical pharmacology in HIV cure research - what impact have we seen?

    abstract::Introduction: Combined antiretroviral therapy (cART) has transformed an inexorably fatal disease into a chronic pathology, shifting the focus of research from the control of viral replication to the possibility of HIV cure. Areas covered: The present review assesses the principal pharmacological strategies that have b...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1561272

    authors: Giacomelli A,de Rose S,Rusconi S

    更新日期:2019-01-01 00:00:00

  • Is single versus combination therapy problematic in the treatment of cutaneous melanoma?

    abstract::Introduction: The development of immunotherapies and targeted therapies has changed the treatment approach in resectable, nonresectable, and metastatic melanoma. Because of their different pharmacological profiles, immunotherapies and/or targeted therapies have been studied in various combinations.Areas covered: We re...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1080/17512433.2019.1650641

    authors: Krattinger R,Ramelyte E,Dornbierer J,Dummer R

    更新日期:2020-03-19 00:00:00

  • Pharmacodynamics of TNF-α inhibitors in psoriasis.

    abstract::Over the last two decades, research developments have revolutionized our understanding of the pathogenesis of psoriasis and of the contribution of several cytokines in the manifestation of the disease. The key role of TNF-α in the pathogenesis of psoriasis has been extensively studied and its therapeutic action, initi...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.11.28

    authors: Vergou T,Moustou AE,Sfikakis PP,Antoniou C,Stratigos AJ

    更新日期:2011-07-01 00:00:00

  • Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?

    abstract::'IDegLira' combines insulin degludec (IDeg) with the glucagon-like peptide-1 analog liraglutide (Lira) at a ratio of 1 unit IDeg to 0.036 mg Lira. The two components have complementary therapeutic actions for the treatment of Type 2 diabetes. Studies have shown that combinations of basal insulin with glucagon-like pep...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.2015.1017562

    authors: Simpson R,King A

    更新日期:2015-03-01 00:00:00

  • Significance and applications of nanoparticles in siRNA delivery for cancer therapy.

    abstract::RNAi is a powerful gene silencing process that holds great promise in cancer therapy by the use of siRNA. The aim of this review is to give an outline on different approaches to deliver siRNA and to describe the advantages and disadvantages of these systems. The prospects for siRNA are to be substantially better than ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.12.33

    authors: Ali HM,Urbinati G,Raouane M,Massaad-Massade L

    更新日期:2012-07-01 00:00:00

  • Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.

    abstract:INTRODUCTION:Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. Despite the known clinical efficacy in relapsed/refractory acute myeloid leukemia (AML), GO was withdrawn from the market in 2010 due to increased e...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1478725

    authors: Baron J,Wang ES

    更新日期:2018-06-01 00:00:00

  • Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response.

    abstract::Inflammation plays a critical role in host defense, maintaining cellular and tissue integrity following chemical, physical and biological insults. Inflammation presents in a variety of acute and chronic disease states and can contribute to disease resolution or progression depending upon the type, magnitude and durati...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.11.66

    authors: Cressman AM,Petrovic V,Piquette-Miller M

    更新日期:2012-01-01 00:00:00

  • The role of the placenta in drug transport and fetal drug exposure.

    abstract:INTRODUCTION:It was assumed for decades that the human placenta serves as a barrier, protecting the fetus from exposure to xenobiotics circulating in the mother. The thalidomide disaster completely reversed this concept. The study of the human placenta is therefore critical to understanding the mechanisms by which xeno...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1425615

    authors: Koren G,Ornoy A

    更新日期:2018-04-01 00:00:00

  • Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles.

    abstract:INTRODUCTION:The Pharmacokinetics/pharmacodynamics (PK/PD) relationships with cytotoxics are usually based on a steepening concentration-effect relationship; the greater the drug amount, the greater the effect. The Maximum Tolerated Dose paradigm, finding the balance between efficacy, while keeping toxicities at their ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1477586

    authors: Rodallec A,Fanciullino R,Lacarelle B,Ciccolini J

    更新日期:2018-06-01 00:00:00

  • What if there were no new antibiotics? A look at alternatives.

    abstract:INTRODUCTION:Bacterial resistance to antibiotics is increasing worldwide, due to the emergence of multidrug-resistant strains. With this panorama, there is a serious danger that we may be entering the 'post-antibiotic era'. Areas covered: We assess why so few new classes of antibiotics have been developed in the past y...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2016.1241141

    authors: Rello J,Bunsow E,Perez A

    更新日期:2016-12-01 00:00:00

  • A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer.

    abstract::Introduction: Patients with early HER2-positive breast cancer (BC) benefit from HER2-targeted systemic therapy. The endorsed standard adjuvant treatment for patients with early HER2-positive breast cancer is chemotherapy plus trastuzumab administered for 1 year. Areas covered: Several trials have investigated modifica...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1552134

    authors: Esposito A,Viale G,Criscitiello C,Curigliano G

    更新日期:2019-01-01 00:00:00

  • Cognitive impairment with diabetes mellitus and metabolic disease: innovative insights with the mechanistic target of rapamycin and circadian clock gene pathways.

    abstract::Introduction: Dementia is the 7th leading cause of death that imposes a significant financial and service burden on the global population. Presently, only symptomatic care exists for cognitive loss, such as Alzheimer's disease.Areas covered: Given the advancing age of the global population, it becomes imperative to de...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1698288

    authors: Maiese K

    更新日期:2020-01-01 00:00:00

  • Clinical applications of pharmacogenomics to adverse drug reactions.

    abstract::The problem of adverse drug reactions is a well-documented global public health problem. Recent withdrawals of several widely used prescription medications in the USA and other countries have raised concerns among patients, clinicians, scientists and policy makers. The increasing interest and concern regarding withdra...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.1.2.251

    authors: Issa AM

    更新日期:2008-03-01 00:00:00

  • A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE).

    abstract::The aim of this article was to assess the efficacy and safety of apremilast in treatment of psoriatic arthritis (PsA) with meta-analysis method. We included four randomized clinical trials identified from MEDLINE, EMBASE, Cochrane Library, "ISRCTN Register" and "ClinicalTrials.gov" which compared apremilast with place...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/17512433.2016.1159130

    authors: Qu X,Zhang S,Tao L,Song Y

    更新日期:2016-06-01 00:00:00

  • Pharmacological resources, diagnostic approach and coordination of care in joint hypermobility-related disorders.

    abstract:INTRODUCTION:Joint hypermobility (JH) is the hallmark of many hereditary soft connective tissue disorders, including Ehlers-Danlos syndromes and related disorders, disorders of the TGFβ-pathway, lateral meningocele syndrome, arterial tortuosity syndrome, and cutis laxa syndromes. Contemporary practice separates individ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1497973

    authors: Baban A,Castori M

    更新日期:2018-07-01 00:00:00

  • Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.

    abstract::Aripiprazole monohydrate (AM) and aripiprazole lauroxil (AL) are two different long-acting injectable formulations of aripiprazole. AM 400 mg administered once monthly demonstrated efficacy in an acute, double-blind, placebo-controlled, randomized clinical trial, as well as in a double-blind, placebo-controlled, rando...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1121809

    authors: Citrome L

    更新日期:2016-01-01 00:00:00